Scarica l'app Stockscreener
32.63
1.17%
-0.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HROW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$33.13
Aprire:
$32.93
Volume 24 ore:
162.56K
Relative Volume:
0.26
Capitalizzazione di mercato:
$1.22B
Reddito:
$272.30M
Utile/perdita netta:
$-5.14M
Rapporto P/E:
-199.57
EPS:
-0.1635
Flusso di cassa netto:
$42.76M
1 W Prestazione:
-5.04%
1M Prestazione:
-17.15%
6M Prestazione:
-5.04%
1 anno Prestazione:
-27.85%
Intervallo 1D:
$32.52
$33.24
Intervallo di 1 settimana:
$32.52
$35.33
Portata 52W:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Nome
Harrow Inc
Settore
Telefono
615.733.4731
Indirizzo
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
32.63 | 1.29B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
18.91 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.04 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.245 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.84 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
496.22 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | BTIG Research | Buy |
| 2025-06-10 | Iniziato | William Blair | Outperform |
| 2025-02-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-04 | Reiterato | B. Riley Securities | Buy |
| 2024-04-11 | Iniziato | Craig Hallum | Buy |
| 2022-09-08 | Ripresa | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2021-09-24 | Iniziato | Aegis Capital | Buy |
| 2021-07-02 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Harrow Inc Borsa (HROW) Ultime notizie
Is Harrow Inc (HROW) a Bargain After 5.7% Drop? GF Value Says Un - GuruFocus
Harrow at Cantor healthcare conference: long view, bigger eye-care bet - investing.com
HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus
Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow to Participate in Three Investor Conferences in September - GlobeNewswire
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move: Shares Move Lower 2.81% at the CloseEarnings Recovery Stocks - dars.gov.et
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - MarketBeat
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Harrow announces product updates - Nashville Post
Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance
Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus
A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus
HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus
HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Harrow Q2 2026 slides: strong demand growth amid profitability push By Investing.com - Investing.com Canada
Harrow Inc Azioni (HROW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Harrow Inc Azioni (HROW) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Option Exercise |
35.96 |
11,250 |
404,550 |
11,250 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Sale |
40.00 |
11,250 |
450,000 |
0 |
| Graves Adrienne L | Director |
May 18 '26 |
Buy |
31.07 |
1,000 |
31,070 |
1,000 |
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
2.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):